GraniteShares 2x Long BULL Daily ETF

Algorhythm

Jiade

Moolec Science SA

Nuveen Real Asset Income and Growth Fund

Atomera

AIM ImmunoTech

Splash Beverage

GraniteShares 2x Long RIVN Daily ETF

Founder

Vivopower

MTSR

IBBQ

<p>Pfizer's 2025 financial report shows that the company demonstrates resilience in its strategic transformation, with a 6% growth in non-COVID core business and a steady 8% growth in oncology. Improved operational efficiency has driven profit enhancement, and the company reaffirms its revenue guidance of $59.5 billion to $62.5 billion for 2026, planning to initiate approximately 20 key clinical trials. Through acquisitions like Metsera, it is positioning itself in growth areas such as obesity, and the oncology pipeline has also made positive progress in indications such as bladder cancer and breast cancer, reflecting a continued deepening of the transition from pandemic-driven to innovation-driven</p>

- On February 3, Pfizer released its 2025 financial report, showing robust operational resilience during its strategic transformation.  
- Total revenues reached $62.6 billion, with a 6% operational growth in core business excluding COVID-19 products, while adjusted earnings per share increased 4% to $3.22.  
- Looking forward to 2026, Pfizer plans to initiate around 20 key clinical trials, aiming to solidify its long-term growth strategies despite declining COVID-19 related product revenues.

Wallstreetcn

Metsera

Invesco Nasdaq Biotechnology ETF

Pacer US Cash Cows Growth ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Direxion Daily F Bull 2X ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares US Pharma

Direxion S&P Biotech Bear 3X

Proshares Ultra Nasdaq Biotech

VG Health

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Pfizer's revenue for the fourth quarter of 2025 was $17.56 billion, with a 9% growth in non-COVID business, and the full-year revenue guidance for 2026 is $59.5-62.5 billion | Financial Report Insights

GraniteShares 2x Long BULL Daily ETF(BULX.US)

Pfizer's revenue for the fourth quarter of 2025 was $17.56 billion, with a 9% growth in non-COVID business, and the full-year revenue guidance for 2026 is $59.5-62.5 billion | Financial Report Insights